Corporate ActionJul 9, 2026, 11:03 AM
AEON Biopharma Updates S-1 Registration Statement Exhibits
AI Summary
AEON Biopharma, Inc. filed an S-1 registration statement, updating its exhibits. The filing includes the Fifth Amendment to the License and Supply Agreement with Daewoong Pharmaceutical Co., Ltd., dated January 21, 2026, and new employment agreements from March 2026. It also lists various forms of warrants, an underwriting agreement, and an Amended and Restated 2023 Incentive Award Plan, reflecting ongoing corporate and financial activities.
Key Highlights
- Filed Fifth Amendment to License and Supply Agreement with Daewoong Pharmaceutical Co., Ltd. on January 21, 2026.
- Included Amended and Restated 2023 Incentive Award Plan from January 21, 2026.
- Added employment agreements for John Bencich and Jennifer Sy from March 9, 2026.
- Listed Form of Underwriting Agreement, suggesting potential capital raising activities.
- Detailed various forms of warrants, including Pre-Funded, Two-Year Milestone, and Five-Year Milestone Warrants.
- Included Form of Warrant Agency Agreement and Form of Warrant Solicitation Agreement.
- Provided Opinion of Sullivan & Worcester LLP and Consent of KPMG LLP.
Price Impact
More from AEON